hifibio-logo
  • About
  • Pipeline
  • DIS® Platform
  • Partnering
  • News
  • Join Us

News

  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
    • Partnerships
    • Open-Innovation Hub
  • News
  • Join Us

Latest News

Jun 18, 2025

HiFiBiO Therapeutics to Present Preclinical Data of Three Leading I&I Programs at the 2025 Annual Meeting of the Federation of Clinical Immunology Societies

All  Filter By:

Jul 3, 2020

Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment

Jul 3, 2020

HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy

Jun 22, 2020

HiFiBiO Therapeutics Presents Three Novel Immuno-Oncology Programs at 2020 AACR Virtual Annual Meeting II

May 15, 2020

HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients

Mar 30, 2020

Droplet Microfluidic Screening and Sequencing Can Vastly Expand the Universe of New Antibody Therapeutics

< 1 … 10 11 12 13 14 … 17 >

oncoverity logo

© 2025 HiFiBiO Therapeutics, Inc.
All Rights Reserved.

Contact

contact@hifibio.com 237 Putnam Ave
Cambridge, MA 02139

Follow Us

Legal

Privacy Policy
Disclaimer
logo
  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
    • Partnerships
    • Open-Innovation Hub
  • News
  • Join Us